gip glp 1 agonists GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications GIP Receptor Agonism Attenuates GLP-1

Finally, the inclusion criteria were not based on histological diagnosis, which could lead to some data contamination due to misdiagnosis

"The Biopharma Patent Cliff: 9 Drugs Losing Exclusivity by the End of 2023"

The ability of GLP-1 RAs to passivate or stabilise plaque requires further evaluation in human studies but may be a novel and important mechanism by which this class confers a reduced risk of future and recurrent ischaemic events, including both MI and ischaemic stroke

doi: 10.1038/aps.2011.149 138 AlmutairiMAl BatranRUssherJR

This is a real game-changer for the development of GLP-1 RAs and peptide therapeutics more broadly